Options for the Management of Attention Deficit/Hyperactivity (ADHD)

Marcia L. Buck, Pharm.D., FCCP, FPPAG

Disclosures

Pediatr Pharm. 2011;17(3) 

In This Article

Transdermal Methylphenidate

The Daytrana® transdermal patch was approved by the Food and Drug Administration in 2006.[1–3,10–12] The three layer patch consists of a polyester/ethylene vinyl acetate laminate film backing, an adhesive layer that contains methylphenidate combined with acrylic and silicone adhesives, and a protective liner that is removed prior to application. Dose varies by patch size. The patch is designed to be worn for 9 hours to provide 12 hours of symptom control, but adjustment of wear times to tailor duration remains the primary reason for selecting this formulation. The location of the patch should be changed daily to reduce skin reactions. Patients and family members must understand the need to carefully dispose of patches to prevent accidental contact or ingestion by children or pets.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....